CSTL
Income statement / Annual
Last year (2023), Castle Biosciences, Inc.'s total revenue was $219.79 M,
an increase of 60.38% from the previous year.
In 2023, Castle Biosciences, Inc.'s net income was -$57.47 M.
See Castle Biosciences, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$219.79 M
|
$137.04 M
|
$94.09 M
|
$62.65 M
|
$51.87 M
|
$22.79 M
|
$13.75 M
|
| Cost of Revenue |
$44.98 M |
$32.01 M |
$15.82 M |
$9.69 M |
$7.31 M |
$5.30 M |
$4.92 M |
| Gross Profit |
$174.81 M |
$105.03 M |
$78.26 M |
$52.96 M |
$44.56 M |
$17.49 M |
$8.83 M |
| Gross Profit Ratio |
0.8 |
0.77 |
0.83 |
0.85 |
0.86 |
0.77 |
0.64 |
| Research and Development
Expenses |
$53.62 M
|
$44.90 M
|
$29.65 M
|
$13.26 M
|
$7.39 M
|
$4.85 M
|
$4.47 M
|
| General & Administrative
Expenses |
$66.50 M
|
$56.40 M
|
$0.00
|
$0.00
|
$0.00
|
$16.47 M
|
$15.26 M
|
| Selling & Marketing
Expenses |
$113.66 M
|
$86.61 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$180.15 M
|
$143.00 M
|
$86.74 M
|
$48.13 M
|
$29.84 M
|
$16.47 M
|
$15.26 M
|
| Other Expenses |
$9.01 M |
$8.27 M |
$1.96 M |
-$1.88 M |
-$2.93 M |
-$272,417.00 |
$163,288.00 |
| Operating Expenses |
$242.78 M |
$196.17 M |
$118.34 M |
$59.51 M |
$37.23 M |
$21.32 M |
$19.73 M |
| Cost And Expenses |
$287.77 M |
$228.18 M |
$134.16 M |
$69.19 M |
$44.54 M |
$26.62 M |
$24.65 M |
| Interest Income |
$10.62 M |
$3.97 M |
$68,000.00 |
$373,000.00 |
$312,000.00 |
$23,514.00 |
$26,184.00 |
| Interest Expense |
$11,000.00 |
$17,000.00 |
$1,000.00 |
$2.63 M |
$4.57 M |
$2.27 M |
$1.65 M |
| Depreciation &
Amortization |
$12.33 M
|
$10.54 M
|
$3.41 M
|
$472,000.00
|
$358,000.00
|
$323,016.00
|
$310,820.00
|
| EBITDA |
-$45.02 M
|
-$58.34 M
|
-$36.61 M
|
-$7.09 M
|
$7.69 M
|
-$3.76 M
|
-$10.40 M
|
| EBITDA Ratio |
-0.2 |
-0.56 |
-0.39 |
-0.09 |
0.1 |
-0.17 |
-0.76 |
| Operating Income Ratio
|
-0.31
|
-0.67
|
-0.43
|
-0.1
|
0.09
|
-0.17
|
-0.79
|
| Total Other
Income/Expenses Net |
$10.61 M
|
$3.95 M
|
$67,000.00
|
-$3.66 M
|
-$1.98 M
|
-$2.52 M
|
-$1.46 M
|
| Income Before Tax |
-$57.37 M |
-$68.90 M |
-$40.01 M |
-$10.20 M |
$5.35 M |
-$6.36 M |
-$12.36 M |
| Income Before Tax Ratio
|
-0.26
|
-0.5
|
-0.43
|
-0.16
|
0.1
|
-0.28
|
-0.9
|
| Income Tax Expense |
$101,000.00 |
-$1.77 M |
-$8.72 M |
$84,000.00 |
$72,000.00 |
$8,606.00 |
$9,731.00 |
| Net Income |
-$57.47 M |
-$67.14 M |
-$31.29 M |
-$10.28 M |
$5.28 M |
-$6.37 M |
-$12.37 M |
| Net Income Ratio |
-0.26 |
-0.49 |
-0.33 |
-0.16 |
0.1 |
-0.28 |
-0.9 |
| EPS |
-2.14 |
-2.58 |
-1.24 |
-0.54 |
0.35 |
-0.6 |
-1.26 |
| EPS Diluted |
-2.14 |
-2.58 |
-1.24 |
-0.54 |
-0.21 |
-0.6 |
-1.26 |
| Weighted Average Shares
Out |
$26.80 M
|
$26.05 M
|
$25.14 M
|
$18.93 M
|
$8.58 M
|
$10.65 M
|
$9.78 M
|
| Weighted Average Shares
Out Diluted |
$26.80 M
|
$26.05 M
|
$25.14 M
|
$18.93 M
|
$8.66 M
|
$10.65 M
|
$9.78 M
|
| Link |
|
|
|
|
|
|
|
